"Anthracyclines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
Descriptor ID |
D018943
|
MeSH Number(s) |
D02.455.426.559.847.562.050 D04.615.562.050 D09.408.051.059
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Anthracyclines".
Below are MeSH descriptors whose meaning is more specific than "Anthracyclines".
This graph shows the total number of publications written about "Anthracyclines" by people in this website by year, and whether "Anthracyclines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2010 | 1 | 0 | 1 |
2011 | 0 | 1 | 1 |
2012 | 2 | 1 | 3 |
2015 | 2 | 1 | 3 |
2016 | 0 | 2 | 2 |
2017 | 1 | 1 | 2 |
2018 | 1 | 1 | 2 |
2019 | 1 | 4 | 5 |
2020 | 0 | 1 | 1 |
2022 | 0 | 2 | 2 |
2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anthracyclines" by people in Profiles.
-
Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis. Support Care Cancer. 2023 Oct 25; 31(12):654.
-
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. Nat Med. 2023 09; 29(9):2268-2277.
-
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med. 2023 08; 12(15):15769-15776.
-
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform. Breast Cancer Res Treat. 2022 Nov; 196(1):57-66.
-
An Updated Review on Radiation Treatment Management in Thymus Cancers. Clin Lung Cancer. 2022 11; 23(7):561-570.
-
Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. Crit Rev Oncol Hematol. 2021 Jan; 157:103143.
-
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Oncologist. 2020 03; 25(3):e589-e597.
-
Anthracycline Exposure and Subsequent Critical Illness: Getting to the Heart of the Problem. Pediatr Crit Care Med. 2019 07; 20(7):672-673.
-
Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. J Clin Oncol. 2019 08 10; 37(23):2072-2081.
-
Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 06 11; 3(11):1714-1721.